FinlandFinland

BioTie and Aventis Develop Drug for Blood Coagulation Disorders

09.04.2004

Turku - Finnish Biotie Therapies Corp. has reached the first milestone agreed in a commercial research and option co-ope-ration signed with Aventis S.A. in early March for the joint development of a new pharmaceutical product for the prevention and treatment of blood coagulation disorders. Consequently, Aventis will pay BioTie a Euro1 million milestone payment in addition to the signing fee (Euro1 million) during April 2004. Under the terms of the agreement, BioTie has granted Aventis an exclusive right to negotiate a license agreement as well as to assess and conduct clinical research on the BioTie-developed products. Aventis will pay BioTie during the next twelve months Euro5 million in signing fees and milestone payments. The agreement follows a preliminary evaluation by Aven-tis of BioTie's bioheparin products which met Aventis' criteria for a New Chemical Entity (NCE) to be used as the basis for a new heparin-like product. BioTie and Aventis are aiming to optimize this NCE, which is designed to become a recom-binant oral heparinoid.

FinlandFinland

08.03.2012

The vaccine research centre of the University of Tampere in Finland has out­licenced a candidate combined prophylactic vaccine against norovirus and rota­virus infections. The Japanese vaccine venture UMN Pharma Inc. acquired the...

FinlandFinland

07.03.2012

Finnish protein manufacturer Vectron Biosolutions AS has completed a study comparing different expression technologies. According to Vectron, their proprietary E. coli expression technology gave higher yields for seven out of ten...

FinlandFinland

02.03.2012

Lappeenranta – Finnish paper industry major UPM plans to invest in an industry-scale biorefinery producing biofuels from crude tall oil, a by-product of the wood pulp manufacturing process. UPM’s total investment will amount to...

FinlandFinland

18.12.2011

Helsinki/Göttingen – Finnish laboratory supplier Biohit Oyj has sold its liquid handling business for €68m to German process and labtech provider Sartorius AG. Osmo Suovaniemi, founder and Chairman of the Board at Biohit,...

FinlandFinland

17.12.2011

Porvoo/Chalfont St. Giles – GE Healthcare and Neste Jacobs have formed a strategic alliance to drive worldwide self-sufficiency in blood plasma fractionation. Finnish-based Neste Jacobs Oy, a global expert in plant engineering...

FinlandFinland

31.10.2011

Bresso/Turku – The wedding's off between Newron and Biotie. The bride has run away. Shares in Italy's Newron Pharmaceuticals plunged after its proposed merger with Biotie Therapies Corp was called off by the Finnish firm....

FinlandFinland

28.09.2011

Turku/ Bresso – It is both good and bad news for the Italian biotechnology sector: Finnish Biotie Therapies ASA has signed an agreement to acquire Newron Pharmaceuticals S.p.A. for €45 million. On the down side, Italy loses one...

FinlandFinland

04.04.2011

Hafnarfjodur – Actavis Group CEO Claudio Albrecht announced at the beginning of February that the company may go public within the next 2-3 years, although it isn’t clear whether the generics manufacturer would conduct an IPO,...

Displaying results 1 to 10 out of 96

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-finland/article/biotie-and-aventis-develop-drug-for-blood-coagulation-disorders.html

Events

All Events

Stock list

All quotes

TOP

  • PHARMING (NL)0.48 EUR11.63%
  • MDX HEALTH (B)3.80 EUR10.79%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK8.53%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.46 EUR-10.26%

TOP

  • WILEX (D)2.82 EUR243.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK44.3%
  • Allergy Therapeutics (UK)20.00 GBP34.4%

FLOP

  • HYBRIGENICS (F)1.72 EUR-28.0%
  • PROSENSA (NL)9.67 USD-23.4%
  • PROTHENA PLC (IE)17.79 USD-21.1%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)431.00 GBP656.1%
  • PAION (D)2.42 EUR272.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.7%
  • CYTOS (CH)0.27 CHF-92.0%
  • PROSENSA (NL)9.67 USD-70.9%

No liability assumed, Date: 31.07.2014


Current issue

All issues

Product of the week

Products